Page 1,570«..1020..1,5691,5701,5711,572..1,5801,590..»

Spain OKs TiGenix’s bigger cell therapy plant as firm preps for Cx601 – BioPharma-Reporter.com

Posted: Published on September 8th, 2017

Spain has licensed TiGenix NV's expanded Madrid plant paving the way for a potential European launch of Cx601, its cell therapy forthe Crohn's disease complications. Belgium-based TiGenix announced it received the Spanish Medicines Agency (AEMPS) license this week, explaining the Madrid plant will provide capacity for production of its portfolio of cell therapies including the candidate cell therapy Cx601. Chief technical officer Wilfried Dalemans said: We have now significantly increased our manufacturing capacity, a key step in the preparation for commercialization of Cx601 in Europe and in the further development of our pipeline. Cx601 has been accepted for review by the European Medicines Agency (EMA) and Swissmedic, which began reviewing TiGenix dossier in June. At the time the firm told us Takeda will take over responsibility for making the cell therapy from 2021 but did not provide additional details. Manufacturing expansion Cx601 is made from stem cells taken from donor adipose tissue. It is being developed for the treatment of complex perianal fistulas in patients with Crohns disease patients who do not otherwise respond to standard therapies. The therapy is madein a 2-dimensional cell culture. TiGenix expanded the Madrid facility with support from Japanese drug firm Takeda, which licensed rights … Continue reading

Posted in Cell Therapy | Comments Off on Spain OKs TiGenix’s bigger cell therapy plant as firm preps for Cx601 – BioPharma-Reporter.com

AbbVie’s positive eczema study drags down Regeneron’s shares – Reuters

Posted: Published on September 7th, 2017

(Reuters) - AbbVie Inc said on Thursday its experimental drug to treat adults with moderate-to-severe eczema met the main goal in a mid-stage study, dragging down shares of rival U.S. biotech firm Regeneron Pharmaceuticals Inc. Eczema, also known as atopic dermatitis, is a chronic skin inflammation, which in severe cases causes constant and often unbearable itching. Regenerons eczema drug, Dupixent, was approved by the U.S. Food and Drug Administration in March. AbbVies mid-stage trial data for its drug, upadacitinib, seemed comparable to Dupixents late-stage data, but the difference in the two studies sample sizes made direct comparisons imprecise, Jefferies analyst Berin Amin said. Nonetheless, we expect upadacitinib to compete with Dupixent, Amin added. Upadacitinib showed a statistically significant improvement in reducing both the severity of eczema in patients and the amount of body area affected by the disease, AbbVie said. Shares of AbbVie, which plans a late-stage study for upadacitinib next year, were up 2.8 percent at $79.23 in late morning trading. Regenerons shares were down 5.2 percent at $474.08. Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Sai Sachin Ravikumar Visit link: AbbVie's positive eczema study drags down Regeneron's shares - Reuters … Continue reading

Posted in Eczema | Comments Off on AbbVie’s positive eczema study drags down Regeneron’s shares – Reuters

AbbVie shares rally on positive eczema study, competitor Regeneron drops – Investing.com

Posted: Published on September 7th, 2017

Investing.com - AbbVie Inc 's (NYSE:) shares climbed on Thursday after the company announced that its mid-stage trial data for its drug, upadacitinib, to treat moderate-to-severe eczema met its primary endpoint. The study showed positive results for upadacitinib with no new safety signals detected, and all doses achieved the primary endpoint of greater mean percentage change from baseline in eczema area and severity index versus a placebo. Clear or almost clear skin was achieved by 50 percent of patients receiving 30 mg once-daily dose of upadacitinib. Upadacitinib is being studied as a once-a-day therapy in eczema (atopic dermatitis) and across multiple immune-mediated diseases. AbbVies shares jumped on the news, but Regeneron Pharmaceuticals shares fell on the potential for new competition for Regeneron's eczema drug, Dupixent, which was approved by the U.S. Food and Drug Administration in March. AbbVies shares were recently up 6.2%, Regenerons were down 6%. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is … Continue reading

Posted in Eczema | Comments Off on AbbVie shares rally on positive eczema study, competitor Regeneron drops – Investing.com

Researchers Turn Skin Cells into Motor Neurons Without Using Stem Cells – Futurism

Posted: Published on September 7th, 2017

Cellular Renovation Why build something from the ground up when one can just renovate an already existing structure? Essentially, thats what researchers from the University of Washington School of Medicine in St. Louis had in mind when they developed a method for transforming adult human skin cells into motor neurons in a lab. They published their work in the journal Cell Stem Cell. In this study, we only used skin cells from healthy adults ranging in age from early 20s to late 60s, senior author Andrew S. Yoo said in a press release. Our research revealed how small RNA molecules can work with other cell signals called transcription factors to generate specific types of neurons, in this case motor neurons. In the future, we would like to study skin cells from patients with disorders of motor neurons. Our conversion process should model late-onset aspects of the disease using neurons derived from patients with the condition. They did this by exposing skin cells in a lab to certain molecular signals usually found at high levels in the human brain. They focused on two short snippets of RNA: microRNAs (mRNAs) called miR-9 and miR-124, which are involved in repurposing the genetic instructions … Continue reading

Posted in Stem Cell Research | Comments Off on Researchers Turn Skin Cells into Motor Neurons Without Using Stem Cells – Futurism

Transformative technology: Encapsulated human cells to … – Medical Xpress

Posted: Published on September 7th, 2017

Professor Che Connon and Dr Stephen Swioklo of Atelerix, a spin-out from Newcastle University, is offering the transformative hydrogel technology for the storage and transport of viable cells including stem cells and cell-based assays at ambient temperatures. Credit: Newcastle University Atelerix, a spin-out from Newcastle University, UK is offering the transformative hydrogel technology for the storage and transport of viable cells including stem cells and cell-based assays at ambient temperatures. This overcomes the barriers presented by the current need for cryo-shipping as it is simple, cell-friendly and offers immediate access to stem cell therapy. This opens up the market for the supply of cells and assays in a ready-to-use format, allowing suppliers to increase the range of assays available to consumers and to scale up their businesses. The breakthrough, patented invention, provides dramatic improvements to an everyday process in a rapidly growing market. Scientific founder, Professor Che Connon of Newcastle University, has been working on the underpinning technology for five years. He said: "Encapsulating cells in the alginate hydrogel is a simple, low cost system capable of preserving the viability and functionality of cells at temperatures between 4 and 21C for extended periods of time. "Used as a method of … Continue reading

Posted in Stem Cell Research | Comments Off on Transformative technology: Encapsulated human cells to … – Medical Xpress

Zika Virus Targets and Kills Brain Cancer Stem Cells – UC San Diego Health

Posted: Published on September 7th, 2017

In developing fetuses, infection by the Zika virus can result in devastating neurological damage, most notably microcephaly and other brain malformations. In a new study, published today in The Journal of Experimental Medicine, researchers at the University of California San Diego School of Medicine and Washington University School of Medicine in St. Louis report the virus specifically targets and kills brain cancer stem cells. The findings suggest the lethal power of the virus notorious for causing infected babies to be born with under-sized, misshapen heads could be directed at malignant cells in adult brains. Doing so might potentially improve survival rates for patients diagnosed with glioblastomas, the most common and aggressive form of brain cancer, with a median survival rate of just over 14 months after diagnosis. The Zika virus specifically targets neuroprogenitor cells in fetal and adult brains. Our research shows it also selectively targets and kills cancer stem cells, which tend to be resistant to standard treatments and a big reason why glioblastomas recur after surgery and result in shorter patient survival rates, said Jeremy Rich, MD, professor of medicine at UC San Diego School of Medicine. Rich is co-senior author of the study with Michael S. Diamond, … Continue reading

Posted in Stem Cell Research | Comments Off on Zika Virus Targets and Kills Brain Cancer Stem Cells – UC San Diego Health

Italian scientists welcome surprise 400 million boost for basic research – Science Magazine

Posted: Published on September 7th, 2017

Italian Minister for Education, University, and Research Valeria Fedeli AP Photo/Luca Bruno By Marta PaterliniSep. 7, 2017 , 4:50 PM Plagued by budget cuts and attacks on science, Italian scientists have had little to cheer about recently. But on Sunday, they received a welcome surprise when Valeria Fedeli, the minister for education, university, and research, announced that Italy will put an extra 400 million into its main basic science fund, the Research Projects of National Interest (PRIN). The money, to be spent over 3 years, will more than quadruple PRINs annual funding. The biggest part of the increase, 250 million, will come out of unused reserves at the Italian Institute of Technology (IIT), a government-funded private foundation in Genoa that has recently come under criticism. This is the largest investment in competitive funds for basic research of the last 20 years, says Elena Cattaneo, a stem cell biologist at the University of Milan and a senator for life in the Italian Parliament who had lobbied for the shift to basic science. PRIN funding has been going up and down since 2002, according to a group of academics calling itselfReturn On Academic ReSearch (ROARS), but overall has been modest. The latest … Continue reading

Posted in Stem Cell Research | Comments Off on Italian scientists welcome surprise 400 million boost for basic research – Science Magazine

Parkinson’s disease cure: THIS common drug could slow progression of condition – Express.co.uk

Posted: Published on September 7th, 2017

Researchers have found evidence that an antidepressant drug could slow progression of Parkinsons disease. A study by Michigan State University discovered that a drug - nortriptyline - can stop the growth of abnormal proteins that can build up in the brain. The drug has been around for more than 50 years and is used to treat depression and nerve pain. However, scientists believe it could have a new purpose. Depression is a very frequent condition associated with Parkinson's, so we became interested in whether an antidepressant could modify how the disease progresses," said Tim Collier, lead study author of the research published in the journal Neurobiology of Disease. Scientists looked at whether patients who had been on antidepressants needed to go on standard Parkinsons treatment later than people who hadnt used antidepressants. Parkinsons sufferers are commonly prescribed a therapy called levodopa. It increases levels of dopamine, which is a natural chemical in the body that sends signals to other nerve cells. The disease can cause levels of dopamine to significantly decrease. "We found that those on a certain class of antidepressant, called tricyclics, didn't need the levodopa therapy until much later compared to those who weren't on that type of … Continue reading

Posted in Parkinson's Treatment | Comments Off on Parkinson’s disease cure: THIS common drug could slow progression of condition – Express.co.uk

Brain chemical lost in Parkinson’s may contribute to its own demise – Science News Magazine

Posted: Published on September 7th, 2017

The brain chemical missing in Parkinsons disease may have a hand in its own death. Dopamine, the neurotransmitter that helps keep body movements fluid, can kick off a toxic chain reaction that ultimately kills the nerve cells that make it, a new study suggests. By studying lab dishes of human nerve cells, or neurons, derived from Parkinsons patients, researchers found that a harmful form of dopamine can inflict damage on cells in multiple ways. The result, published online September 7 in Science, brings multiple pieces of the puzzle together, says neuroscientist Teresa Hastings of the University of Pittsburgh School of Medicine. The finding also hints at a potential treatment for the estimated 10 million people worldwide with Parkinsons: Less cellular damage occurred when some of the neurons were treated early on with antioxidants, molecules that can scoop up harmful chemicals inside cells. Study coauthor Dimitri Krainc, a neurologist and neuroscientist at Northwestern University Feinberg School of Medicine in Chicago, and colleagues took skin biopsies from healthy people and people with one of two types of Parkinsons disease, inherited or spontaneously arising. The researchers then coaxed these skin cells into becoming dopamine-producing neurons. These cells were similar to those found in … Continue reading

Posted in Parkinson's Treatment | Comments Off on Brain chemical lost in Parkinson’s may contribute to its own demise – Science News Magazine

Sumitomo Dainippon Seeks Japanese Approval for Trerief to Treat Parkinsonism in Dementia Patients – Parkinson’s News Today

Posted: Published on September 7th, 2017

Sumitomo Dainippon Pharma has asked Japanese authorities to approve itsTrerief (zonisamide) as a new therapy for parkinsonismin dementia patients with Lewy bodies, the company announced in a press release. Trerief went on sale in Japan in March 2009 as a treatment for Parkinsonspatients who saw insufficient results with levodopa and other Parkinsons-specific drugs. After a 2013 expansion of its originalapproval, Trerief is now accepted as a treatment option inJapan, where a2014 Patient Surveyreported some144,000 patients suffering from vascular dementia and unspecified dementia,including dementia with Lewes bodies (DLB). Parkinsonism is a general term used to describe a group of neurological disorders that cause movement problems similar to those observed in Parkinsons disease, like tremors, slow movement and stiffness. The DLB form of dementia causes progressive cognitive impairment. Parkinsonism is one of the four core features of DLB, alongside fluctuating cognition, recurrent visual hallucinations and rapid eye movement (REM) sleep behavior disorder. DLB is classified as part of the Lewy body disease spectrum, which also includes Parkinsons disease. Since symptoms of parkinsonism virtually mimic those of Parkinsons disease, Sumitomo Dainippon is now seeking approval for Trerief as another therapeutic option for treating parkinsonism in DLB, under the assumption that its action will … Continue reading

Posted in Parkinson's Treatment | Comments Off on Sumitomo Dainippon Seeks Japanese Approval for Trerief to Treat Parkinsonism in Dementia Patients – Parkinson’s News Today

Page 1,570«..1020..1,5691,5701,5711,572..1,5801,590..»